Virtu Financial BD LLC recently announced the acquisition of new stake in vTv Therapeutics Inc. (NASDAQ:VTVT). The institutional investor has increased its shareholding in the Healthcare company by 13.99% to 43954.0 shares with purchase of 5395.0 shares. This fresh investment now brings its stake to 0.05% valued currently at $29142.0.
With over 0.13 million vTv Therapeutics Inc. (VTVT) shares trading Friday and a closing price of $1.01 on the day, the dollar volume was approximately $0.13 million. The shares have shown a positive half year performance of 37.43% and its price on 01/20/23 gained nearly 2.38%. Currently, there are 80.49M common shares owned by the public and among those 28.94M shares have been available to trade.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 3 analysts who have offered their price forecasts for VTVT have a consensus price objective of $4.00. The analysts have set the share’s price value over the next 12 months at a high of $6.00 and a low of $2.00. The average price target is 76.67% above its recent price level and an upside to the estimated low will see the stock gain 49.5% over that period. But an upside of 83.17% will see the stock hit the forecast high price target while median target price for the stock is $4.00.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 61,000 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in vTv Therapeutics Inc. are Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu. Vanguard Total Stock Market Index owns 0.63 million shares of the company’s stock, all valued at over $0.41 million. Vanguard Extended Market Index Fu bought 653.0 shares to see its total holdings expand to 0.31 million shares valued at over $0.2 million and representing 0.37% of the shares outstanding. Fidelity Extended Market Index Fu now owns shares totaling to 0.19% of the shares outstanding.
Shares of vTv Therapeutics Inc. (NASDAQ: VTVT) opened at $1.00, up $0.01 from a prior closing price of $0.99. However, the script later moved the day high at 1.0500, up 2.38%. The company’s stock has a 5-day price change of 24.69% and 23.14% over the past three months. VTVT shares are trading 52.38% year to date (YTD), with the 12-month market performance up to 21.29% higher. It has a 12-month low price of $0.38 and touched a high of $1.40 over the same period. VTVT has an average intraday trading volume of 68.35K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 32.47%, 26.35%, and 23.17% respectively.
Institutional ownership of vTv Therapeutics Inc. (NASDAQ: VTVT) shares accounts for 4.30% of the company’s 80.49M shares outstanding. Mutual fund holders own 1.53%, while other institutional holders and individual stakeholders account for 75.70% and 0.77% respectively.
It has a market capitalization of $103.20M and a beta (3y monthly) value of -1.16. The earnings-per-share (ttm) stands at -$0.31. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.18% over the week and 7.89% over the month.
Analysts forecast that vTv Therapeutics Inc. (VTVT) will achieve an EPS of -$0.04 for the current quarter, -$0.06 for the next quarter and -$0.3 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.06 while analysts give the company a high EPS estimate of -$0.03. Comparatively, EPS for the current quarter was -$0.02 a year ago. Earnings per share for the fiscal year are expected to decrease by -18.60%, and -23.10% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 3 brokerage firm advisors rate vTv Therapeutics Inc. (VTVT) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 3 Wall Street analysts polled rate the stock as a buy, while 0 of the 3 advise that investors “hold,” and 0 rated it as a “Sell.”
Stifel coverage for the vTv Therapeutics Inc. (VTVT) stock in a research note released on April 10, 2018 offered a Hold rating with a price target of $1. ROTH Capital was of a view on March 08, 2018 that the stock is Buy, while Northland Capital gave the stock Outperform rating on February 08, 2018, issuing a price target of $28. H.C. Wainwright on their part issued Buy rating on September 26, 2016.
